StockNews.com Initiates Coverage on ObsEva (NASDAQ:OBSV)

Stock analysts at StockNews.com started coverage on shares of ObsEva (NASDAQ:OBSV) in a report released on Saturday. The firm set a “hold” rating on the stock.

ObsEva Stock Performance

Shares of NASDAQ OBSV opened at $0.00 on Friday. ObsEva has a 52-week low of $0.08 and a 52-week high of $2.14. The firm has a 50 day moving average price of $0.02 and a two-hundred day moving average price of $0.04. The stock has a market cap of $155,942.00, a P/E ratio of 0.00 and a beta of 0.68.

Hedge Funds Weigh In On ObsEva

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Credit Suisse AG increased its position in shares of ObsEva by 11.0% during the fourth quarter. Credit Suisse AG now owns 1,750,573 shares of the company’s stock worth $255,000 after buying an additional 173,455 shares during the period. Bank of America Corp DE increased its position in shares of ObsEva by 54,142.2% during the first quarter. Bank of America Corp DE now owns 484,383 shares of the company’s stock worth $731,000 after buying an additional 483,490 shares during the period. Two Sigma Investments LP acquired a new stake in shares of ObsEva during the third quarter worth $25,000. Millennium Management LLC acquired a new stake in shares of ObsEva during the second quarter worth $192,000. Finally, XTX Topco Ltd increased its position in shares of ObsEva by 33.9% during the first quarter. XTX Topco Ltd now owns 79,757 shares of the company’s stock worth $120,000 after buying an additional 20,196 shares during the period. 17.52% of the stock is currently owned by institutional investors and hedge funds.

ObsEva Company Profile

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.